Retention in PrEP Care for African American MSM in Mississippi

NCT ID: NCT03256435

Last Updated: 2021-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-07

Study Completion Date

2021-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Innovative and novel HIV prevention interventions are urgently needed for African American (AA) young men who have sex with men (YMSM) in the South, and in Mississippi in particular. HIV pre-exposure prophylaxis (PrEP) is a newer HIV prevention strategy that consists of a daily oral antiretroviral pill taken on an ongoing basis by HIV-uninfected but at-risk individuals. Although acceptability studies have demonstrated high interested in PrEP in the US, uptake remains limited. To date, studies of PrEP initiation have largely been limited to settings in which PrEP is provided free of charge. Barriers to PrEP initiation and retention in PrEP care in real world settings are likely more complex, since payment for PrEP can be a substantial financial burden.

The ADAPT\_ITT approach (an approach to adapting behavioral interventions to new populations: Assessment, Decision, Administration, Production, Topical Experts - Integration, Training, Testing) will be used to develop and pilot test a RAMP (Retain African American Men in PrEP) intervention that aims to promote PrEP adherence and retention in care in Jackson, MS and focuses on recruiting AA YMSM in a city with some of the highest HIV infection rates in the country. This study will include formative research to understand the cultural and social contexts that influence AA YMSM's PrEP use patterns and the acceptability of our proposed intervention. Results from these qualitative interviews will inform the study intervention which will be tested and refined in a dynamic open pilot evaluation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Men who have sex with men (MSM) bear a disproportionate burden of the HIV epidemic in the United States (US), and the number of new HIV diagnoses among MSM is increasing every year. Despite HIV incidence remaining relatively stable overall, HIV incidence is increasing among MSM, and among Black/African American (hereafter AA) young MSM (YMSM) in particular. Black/AA MSM represent less than 1% of the population but account for 25% of new HIV diagnoses. Compared to MSM of other races, AA MSM are 3 times more likely to be HIV infected. Among YMSM, the disparities are greatest; AA MSM aged 20-29 have an HIV prevalence of 34%, whereas White MSM in the same age range have an HIV prevalence of 5.5%. Additionally, the American South accounts for 46% of new HIV diagnoses in the US and 45% of new AIDS diagnoses. Mississippi is ranked 7th in the country in HIV case rates, with an overall rate of 20.7 per 100,000 persons; however, some census tracts have rates of 2-5%, which is comparable to some sub-Saharan African countries. There are alarming racial disparities related to HIV/AIDS; in Mississippi, AAs comprise 37% of the population but accounted for 76% of HIV infection reported in 2013. Between 2011 and 2013, the number of infections among MSM in Mississippi increased 43%, with an even sharper increase among AA YMSM, who have among the highest rates of infection in the nation.

Given the disproportionate burden of HIV, worse HIV outcomes, and current social climate, innovative and novel HIV prevention interventions are urgently needed for AA YMSM in the South, and in Mississippi in particular. HIV pre-exposure prophylaxis (PrEP) is a newer HIV prevention strategy that consists of a daily oral antiretroviral pill taken on an ongoing basis by HIV-uninfected but at-risk individuals. Its efficacy has been well established in randomized controlled trials and open-label studies for MSM and other groups. Although acceptability studies have demonstrated high interest in PrEP in the US, uptake remains limited. To date, studies of PrEP initiation have largely been limited to settings in which PrEP is provided free of charge. Barriers to PrEP initiation and retention in PrEP care in real world settings are likely more complex, since payment for PrEP can be a substantial financial burden. Although most health insurance programs are covering the cost of PrEP, and the industry-sponsored PrEP Medication Assistance Program exists to assist people who do not have insurance, these programs require patient and clinician awareness, sufficient staffing and appropriate infrastructure.

A body of evidence is only beginning to emerge related to PrEP adherence and little is known about retention in PrEP care, most of which is in the context of either RCTs or open-label studies in which PrEP is provided free of charge. The efficacy of PrEP is closely tied to adherence, and evidence suggests that efficacy decreases exponentially with fewer doses of PrEP per week; maximum efficacy is achieved when 6-7 doses are taken per week, but PrEP provides high protection with at least 4 doses per week. In an open label study of PrEP uptake and adherence in MSM, 71% of participants receiving PrEP had drug detected after initiation of PrEP. AA YMSM in Jackson, MS face many challenges to optimal adherence and retention in care, including inconsistent routines, socioeconomic challenges, and logistical difficulty in returning for follow-up visits. MSM may not want to disclose use of PrEP to family or friends, due to the potential for unintended disclosure of sexual orientation, which may result in reduced social support for PrEP adherence or returning for care. Understanding barriers and facilitators to adherence and retention in care for AA YMSM, and subsequently the development of interventions to improve them, will be necessary to ensure maximum PrEP effectiveness.

The ADAPT\_ITT approach will be used to develop and pilot test a RAMP intervention that aims to promote PrEP adherence and retention in care in Jackson, MS and focuses on recruiting AA YMSM in a city with some of the highest HIV infection rates in the country. This study will include formative research to understand the cultural and social contexts that influence AA YMSM's PrEP use patterns and the acceptability of our proposed intervention. Results from these qualitative interviews will inform the study intervention which will be tested and refined in a dynamic open pilot evaluation.

Qualitative interviews (Phase 1) will "assess" individual, interpersonal and structural contexts of sexual risk behavior, anticipated adoption and use of new prevention technologies, barriers and facilitators to PrEP initiation and adherence, and optimal content and format for a PrEP initiation and adherence intervention. Using results of the qualitative interviews and input from key opinion leaders, the investigators will "decide" on intervention components and structure of the intervention package. The investigators will then "adapt" the Life-Steps intervention to be responsive to the unique context and complex needs of AA YMSM in Jackson, and "produce" a draft of the intervention manual. Our study team is made up of "topical experts" who will all have a central role in developing the intervention manual. Moreover, the open pilot evaluation (Phase 2) will be used to obtain further input on the draft intervention manual and protocol. After "integrating" the feedback obtained from the open pilot evaluation and exit interviews into the intervention manual and protocol, study staff will be "trained" in all final study procedures, and a provisional theory-based intervention to overcome barriers to PrEP adherence and retention, and reduce sexual risk behavior, among AA YMSM will be "tested" in a pilot Randomized Control Trial (RCT) (Phase 3). This intervention will have broad generalizability for AA YMSM across the South and the country as PrEP programs expand nationwide.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preventive Medicine HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

RAMP PrEP initiation, adherence, and retention intervention package as well as standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)

Group Type EXPERIMENTAL

RAMP PrEP initiation, adherence, and retention intervention

Intervention Type BEHAVIORAL

The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.

Control Arm

Standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RAMP PrEP initiation, adherence, and retention intervention

The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-35 years of age
* assigned male sex at birth
* African American race
* report having sex with another person assigned male at birth who identifies as a man within the last year
* report behavioral risk for HIV infection (consistent with the CDC guidelines for prescribing PrEP: unprotected anal intercourse (UAI) with at least one HIV-infected or unknown serostatus partner in the preceding 6 months)
* HIV-uninfected by antibody test
* able to understand and speak English (for consenting and counseling).

Exclusion Criteria

* unable to provide informed consent, including people with severe mental illness requiring immediate treatment or with mental illness limiting their ability to participate
* for aims 2 and 3 only, participants who are positive for Hepatitis B antigen or diagnosed with renal insufficiency (Glomerular Filtration Rate\<50)
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Mississippi Medical Center

OTHER

Sponsor Role collaborator

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

Brown University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amy S Nunn, ScD

Role: PRINCIPAL_INVESTIGATOR

Brown University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Open Arms Clinic

Jackson, Mississippi, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Goedel WC, Coats CS, Chan PA, Sims-Gomillia CE, Brock JB, Ward LM, Mena LA, Nunn AS. A Pilot Study of a Patient Navigation Intervention to Improve HIV Pre-exposure Prophylaxis Persistence Among Black/African American Men Who Have Sex With Men. J Acquir Immune Defic Syndr. 2022 Jul 1;90(3):276-282. doi: 10.1097/QAI.0000000000002954.

Reference Type DERIVED
PMID: 35312652 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5R34MH109371-03

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1611001642

Identifier Type: -

Identifier Source: org_study_id